Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding durvalumab to EP for ES-SCLC improves overall survival

Key clinical point: Adding durvalumab to first-line EP improves survival in ES-SCLC.

Major finding: Overall survival at 18 months was 33.9% with D+EP vs. 24.7% with EP.

Study details: Interim findings in 537 patients from the open-label phase 3 CASPIAN trial.

Disclosures: The CASPIAN trial was sponsored by AstraZeneca. Dr. Paz-Ares reported financial relationships with several pharmaceutical companies including AstraZeneca. Dr. Ahn reported receiving honoraria from, and/or serving as a consultant or adviser for AstraZeneca, Bristol-Myers Squibb, Ono, Merck Sharp & Dohme, Takeda, Boehringer Ingelheim, Roche, and Alpha Pharmaceuticals.


Paz-Ares L et al. WCLC 2019. Overall survival with durvalumab plus etoposide-platinum in first-line extensive-stage SCLC Abstract PL02.11.